Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
With outbreaks of cold and flu on the rise across the U.S., Americans are facing a seemingly impossible task of helping their families stay healthy this winter. As of last week, the U.S. Centers for Disease Control and Prevention (CDC) reported that 47 states have declared the incidence of flu to be regional or widespread in their communities and nearly 10,000 cases of H1N1 have been documented.
Pandemrix is an influenza vaccination, created in 2009 to combat H1N1, known as Swine Flu. Now, a team of Swedish clinicians testing the vaccine for links to immune-related or neurological diseases have linked Pandemrix to an increased risk of narcolepsy in young adults.
Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9).
Colonial Manor Cleburne, Advanced Healthcare of Garland and Winfield Rehab and Nursing, top-notch rehabilitation and skilled nursing centers, located in Cleburne, Garland, and Crockett, Texas, will be providing free flu shots to seniors 65 and above on January 22, 23 & 27 2014 from 10 AM - 2 PM.
McGill researchers, led by Dr. Maya Saleh of the Department of Medicine, have identified an enzyme, cIAP2 that helps the lungs protect themselves from the flu by giving them the ability to resist tissue damage. "It's a discovery that offers exciting new avenues for controlling influenza, since until now attempts to target the virus itself have proven challenging, especially in the face of emerging new strains of the virus," says Saleh, who is also a researcher at the Research Institute of the McGill University Health Centre.
Research indicated that some Indigenous people such as in Alaska and Australia displayed limited immunity response to the effects of influenza.
Meridian Bioscience, Inc. today announced that the company's TRU FLU assay received FDA clearance for an analytical sensitivity claim for the novel avian Influenza H7N9 strain, A/Anhui/1/2013. TRU FLU is a rapid immunoassay that detects influenza A and influenza B viruses in 15 minutes in human respiratory specimens.
CEL-SCI Corporation, a late-stage oncology company, today announced that it has closed an underwritten public offering of units consisting of an aggregate of 5,238,095 shares of common stock and warrants to purchase an aggregate of 5,238,095 shares of common stock. The
In the case of a bioterror attack, Saint Louis University will operate a medication dispensing station for students, faculty, staff and their families, offering quick access to medicines and easing the burden on local health departments so they can serve residents who lack similar access to lifesaving drugs.
Researchers have identified immune cells in patients with narcolepsy that react against hypocretin, the lack of which causes the disorder.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
With cold and flu season now in full swing, all-natural wellness provider Neutra Corp. (OTCBB: NTRR) is working quickly to deliver a revolutionary new antimicrobial coating that could soon prove to be the best defense against infections and viruses in the most notorious hotspot for the spread of these diseases: the classroom.
ATS Labs announced today that they are pleased to offer testing of antimicrobial products for efficacy against avian influenza A (H7N9) virus. Avian influenza A (H7N9) virus, called H7N9 for short, has infected humans in China causing severe respiratory illness.
Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).
A research team consisting of more than 60 collaborators in 26 countries has estimated the global death toll from the 2009 outbreak of the H1N1 virus to be 10 times higher than the World Health Organization's count, which was based on laboratory-confirmed cases of this flu. The study, which appears online in PLOS Medicine, suggests that the pandemic virus caused up to 203,000 respiratory deaths around the world.
With autumn just around the corner and a new flu strain lying in wait for us, the presentation of a study analysing the management of the 2009 influenza A crisis could not, if anything, be better timed.
Researchers at the University of California, San Diego School of Medicine have shown for the first time how influenza A viruses snip through a protective mucus net to both infect respiratory cells and later cut their way out to infect other cells.
A new University of Michigan study found that the state immunization registry - the public health database that tracks vaccinations- can be an effective tool to encourage influenza vaccinations during a pandemic.
Neutra Corp., a growing provider of all-natural wellness solutions, announced today that its joint venture partner Surface to Air Solutions is finalizing the acquisition of a sanitation technology innovator dedicated to greatly reducing the risk of staph infection in sports.
NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.